Home › Funds › Stonepine Capital Management, LLC › XFOR

Stonepine Capital Management, LLC position in XFOR

X4 PHARMACEUTICALS INC · Health Care

Stonepine Capital Management, LLC reported holding 224,989 shares of XFOR (X4 PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$1.1M, representing 0.69% of its reported portfolio and ranking #35 among its reported holdings. Stonepine Capital Management, LLC has disclosed XFOR holdings in 5 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)224.99K sh
Reported value held$1.05M
Portfolio Weight0.69%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Stonepine Capital Management, LLC's XFOR position evolved

Stonepine Capital Management, LLC first disclosed a stake in XFOR in Q3 2023 at 5,273,685 shares (US$5.7M). Across 5 filings, Stonepine Capital Management, LLC increased the stake 0 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 224,989 shares valued at US$1.1M — a reduction of -110,320 shares quarter over quarter.. Notable position changes include a 44% trim in Q4 2025 (shares rose 3% over the following quarter), a 44% trim in Q1 2026 (shares rose 13% over the following quarter), a 33% trim in Q2 2026 (shares fell 38% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 5.27M $5.75M New
Q3 2025 1.06M $3.61M New
Q4 2025 593.57K $2.37M Reduce
Q1 2026 335.31K $1.38M Reduce
Q2 2026 224.99K $1.05M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XFOR and 13F data

XFOR (X4 PHARMACEUTICALS INC) is a Health Care company. 40 other funds we track also report a position in XFOR — the largest reported positions include Bain Capital Life Sciences Investors, LLC (US$37.2M), PERCEPTIVE ADVISORS LLC (US$37.0M), Saturn V Capital Management LP (US$32.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XFOR

All XFOR fund holders →

FAQ

How long has Stonepine Capital Management, LLC held XFOR?

Stonepine Capital Management, LLC has disclosed XFOR holdings in 5 of the last 12 reported quarters, going back to Q3 2023.

What is Stonepine Capital Management, LLC's current position in XFOR?

As of Q2 2026, Stonepine Capital Management, LLC holds 224.99K shares of XFOR (X4 PHARMACEUTICALS INC), valued at $1.05M, representing 0.69% of its reported portfolio and ranking #35.

Has Stonepine Capital Management, LLC been buying or selling XFOR?

In the latest 13F filing (Q2 2026), Stonepine Capital Management, LLC reduced its position in XFOR.

Which other funds hold XFOR?

Other major institutional holders of XFOR include Bain Capital Life Sciences Investors, LLC, PERCEPTIVE ADVISORS LLC, Saturn V Capital Management LP, among 40 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.